Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials

Federica Cuppone(Italian Medicines Agency), Paolo Carlini(National Cancer Institute)

BMC Cancer

December 1, 2010

10.1186/1471-2407-10-675

Cited by 23

Related Papers

Lonidamine: Efficacy and safety in clinical trials for thetreatment of solid tumors

|Drugs of today|2003|168

Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients

|Oncology|2005|133

Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide

|Journal of Clinical Oncology|2005|96

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

|The Lancet Oncology|2018|88

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease

|Annals of Oncology|2006|82